FDA Drug Recalls
1,134 recalls, newest first
Oct 3, 2017
Class III · Low risk
Failed impurities/degradation specifications: Famotodine has an out of specification result for an individual related substance observed during routine stability testing of a batch for related substances -impurity 8 at 24 month stability interval.
Oct 2, 2017
Class II · Moderate risk
Failed Impurities/Degradation Specifications: Out of Specification for an unknown impurity was observed during the 18 month stability testing.
Sep 28, 2017
Class II · Moderate risk
Labeling: Label Error on Declared Strength. Bottle labeled as 0.5 mg tablets contained 1mg tablets of lorazepam
Sep 27, 2017
Class II · Moderate risk
Microbial Contamination of Non-Sterile Products
Sep 27, 2017
Class II · Moderate risk
CGMP Deviations; FDA analysis deterrmined that the product does not contain glutamine and two unknown impurities were observed
Sep 26, 2017
Class II · Moderate risk
Sep 26, 2017
Class III · Low risk
Labeling: Incorrect or Missing Lot and/or Exp. Date
Sep 26, 2017
Class III · Low risk
Labeling: Incorrect or Missing Lot and/or Exp. Date
Sep 26, 2017
Class III · Low risk
Labeling: Incorrect or Missing Lot and/or Exp. Date
Sep 26, 2017
Class II · Moderate risk
Failed Impurities/Degradation Specifications: Out-of-specification result for an unknown impurity.
Sep 25, 2017
Class III · Low risk
Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.
Sep 25, 2017
Class III · Low risk
Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.
Sep 25, 2017
Class III · Low risk
Labeling: Missing Label: customer complaint that some vials of ampicillin within the shrink wrap pack are missing labels.
Sep 25, 2017
Class III · Low risk
Subpotent Drug: low out of specification results.
Sep 25, 2017
Class II · Moderate risk
Lack of Assurance of Sterility; autoclave parameters were not correct for one of two autoclaves used to sterilize the product.
Sep 22, 2017
Class III · Low risk
Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.
Sep 21, 2017
Class II · Moderate risk
Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.